Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Sabrina Z WangBrad PooreJesse AltAntoinette PriceSariah J AllenAllison R HanafordHarpreet KaurBrent A OrrBarbara S SlusherCharles G EberhartEric H RaabeJeffrey A RubensPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Unbiased metabolic profiling of AT/RT identified susceptibility of high MYC AT/RT to glutamine metabolic inhibition with DON therapy. DON inhibited glutamine-dependent synthesis of GSH and synergized with carboplatin to extend survival in high MYC AT/RT. These findings can rapidly translate into new clinical trials to improve survival in high MYC AT/RT.